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for urinary adiponectin and their 
application as novel biomarkers 
for diabetic kidney disease
toshihiro Watanabe1*, Yuki fujimoto2, Aya Morimoto3, Mai nishiyama3, Akinori Kawai3, 
Seiki okada3, Motohiro Aiba2, tomoharu Kawano4, Mina Kawahigashi4, Masashi ishizu5, 
Hiroyasu Mori5, Munehide Matsuhisa5, Akiko Hata6, Makoto funaki6 & Seiichi Hashida7
Glomerular filtration rate (GFR) and urinary albumin excretion rate (UAER) are used to diagnose 
and classify the severity of chronic kidney disease. Total adiponectin (T-AN) and high molecular 
weight adiponectin (H-AN) assays were developed using the fully automated immunoassay system, 
HI-1000 and their significance over conventional biomarkers were investigated. The T-AN and H-AN 
assays had high reproducibility, good linearity, and sufficient sensitivity to detect trace amounts 
of adiponectin in the urine. Urine samples after gel filtration were analyzed for the presence of 
different molecular isoforms. Low molecular weight (LMW) forms and monomers were the major 
components (93%) of adiponectin in the urine from a diabetic patient with normoalbuminuria. Urine 
from a microalbuminuria patient contained both high molecular weight (HMW) (11%) and middle 
molecular weight (MMW) (28%) adiponectin, although the LMW level was still high (52%). The amount 
of HMW (32%) and MMW (42%) were more abundant than that of LMW (24%) in a diabetic patient 
with macroalbuminuria. T-AN (r = − 0.43) and H-AN (r = − 0.38) levels showed higher correlation 
with estimated GFR (eGFR) than UAER (r = − 0.23). Urinary levels of both T-AN and H-AN negatively 
correlated with renal function in diabetic patients and they may serve as new biomarkers for diabetic 
kidney disease.
Chronic kidney disease (CKD) is a disease, in which chronic renal impairment or decline in renal function is 
followed by an end-stage renal disease that requires dialysis or a kidney  transplant1. In addition, CKD has been 
shown to increase the risk of cardiovascular disease (CVD) such as myocardial infarction, stroke, and heart 
failure, as well as  death2. Therefore, early diagnosis and appropriate treatment of CKD is critical to prevent the 
onset/progression of CKD and the development of CVD. Glomerular filtration rate (GFR) and urinary albumin 
excretion rate (UAER) have been used to diagnose and classify the severity of  CKD3, and previous studies have 
shown that urinary adiponectin may be useful as a biomarker of CKD, as well.
Several studies have confirmed that urinary adiponectin increases with the progression of renal impairment 
in patients with  diabetes4–6. It has also been reported that predicting the onset/progression of such impairments 
by either GFR or UAER is difficult, but urinary adiponectin levels may enable this  prediction7,8. Furthermore, 
increased urinary adiponectin has been reported in IgA  nephropathy9 and in nephropathy caused by systemic 
lupus  erythematosus10,11. Urinary adiponectin has been thought to be excreted due to either disruption of the 
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glomerular  barrier8–10, tubular  injuries8,12 or vascular  damages13, and it is of interest to investigate if urinary 
adiponectin would have significance as a biomarker over other conventional biomarkers in diabetic kidney 
disease (DKD).
Immunoassay technology is widely used for detection of protein biomarkers and novel technologies are 
continuing to be  developed14–21. Adiponectin is present in urine at very low concentrations (pg/mL levels)4–13 
and a commercial immunoassay kit do not have sufficient analytical sensitivity to detect these trace  amounts10. 
In recent years, an ultrasensitive immunoassay system capable of measuring down to a concentration of pg/
mL or less has been put into practical  use22,23. Immune complex transfer enzyme immunoassay (ICT-EIA) 24, 
which is one of the methods to realize ultrasensitive immunoassay detection, can be adapted to high-throughput 
immunoassay systems used in clinical  settings25–28. Using antibody-coated magnetic particles to increase capture 
efficiency, immune complex transfer enables interfering background signal to be eliminated, thereby enhancing 
analytical sensitivity.
Previously, we developed a manual ICT-EIA to detect trace amounts of total adiponectin (T-AN) in  urine29.
We have also reported that patients with diabetes show increased T-AN levels in their urine, in spite of a decrease 
in their blood, when compared with healthy and obese subjects. Analysis of urine by gel filtration revealed that 
urine T-AN consists of four isoforms, which are high molecular weight (HMW), medium molecular weight 
(MMW), low molecular weight (LMW), and monomers. HMW adiponectin (H-AN) is increased in the urine 
of a patient with microalbuminuria compared with that in the urine of a patient with normoalbuminuria. Fur-
thermore, T-AN concentrations, but not UAER, shows a significant correlation with eGFR. As a result, urinary 
adiponectin may be a useful surrogate marker for the decline of eGFR.
As described above, the molecular morphology of urinary adiponectin may be altered in response to the 
progression of DKD. Therefore, we developed a method, which is capable of differentially quantifying all adi-
ponectin isoforms, which is sensitive enough to detect trace amounts of them found in the urine. T-AN assays, 
which we reported  previously29, was performed manually with multiple steps. Thus, it is complicated and time 
consuming, and it may be challenging to conduct in clinical situations. In this paper, we demonstrate our fully 
automated ultrasensitive T-AN assay and a new H-AN assay, which is also ultrasensitive and fully automated. 
Furthermore, we show the significance of these two assays as new biomarkers for DKD.
Results
Reactivities of T-AN and H-AN assays to adiponectin multimers and monomer fractions. A 
urine sample obtained from a patient with macroalbuminuria was fractionated using size exclusion chromatog-
raphy (SEC) and fractions were analyzed using both T-AN and H-AN assays (Fig. 1). Similar to our previous 
study, in which T-AN assays were conducted  manually29, 4 peaks, which correspond to HMW, MMW, LMW and 
monomeric adiponectin, respectively, were observed by the T-AN assay. In contrast, the H-AN assay generated 
a single peak that corresponded to HMW adiponectin, although a weak signal without a peak was also detected 
in fractions corresponding to MMW adiponectin. However, the MMW signal is remarkably low compared to 
the signal corresponding to HMW, demonstrating the specificity of our H-AN assay for reporting the amount 
of HMW in the urine.
Figure 1.  Reactivities of T-AN and H-AN assays to multimers and monomer fractions of urinary adiponectin. 
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Analytical performance of T-AN and H-AN assays. Analytical performance of T-AN and H-AN 
assays are shown in Fig. 2. Dose and response curves were obtained for these two assays (Fig. 2a,b) and LoDs 
(Limits of Detection) were calculated as 0.05 and 0.11 pg/mL for T-AN and H-AN assays, respectively, using 
the mean plus 3SD of low concentration samples. Reproducibility was good with CVs of 1.8–2.6% and 2.1–5.1% 
(n = 10) for T-AN and H-AN assays, respectively. In testing of serially diluted samples (Fig. 2c,d), the ratios of 
the observed concentrations to the expected concentrations based on the dilution factor in the T-AN and H-AN 
assays were 93–100% and 98–103%, respectively.
A manual ICT-EIA for T-AN was previously developed and a feasibility study of urinary T-AN levels as a CKD 
biomarker was  reported29. The newly developed T-AN assay uses the same antibody pair, and has a comparable 
sensitivity with the manual ICT-EIA, while the assay time was shortened from 3 days to 1 h because of the fully 
automated process on HI-1000. A measurement by the manual ICT-EIA and a measurement by the T-AN assay 
on HI-1000 showed a strong correlation (Fig. 3). However, for samples containing high levels of T-AN (above 
50 μg/gCr), the measurement on HI-1000 tended to be lower than that by the manual ICT-EIA (Fig. 3a). When 
those samples were excluded, the slope was close to 1 (Fig. 3b).
composition of adiponectin multimers in the urine of DKD patients. In addition to the data of 
a patient with macroalbuminuria shown in Fig. 1, urine samples from a patient with normoalbuminuria and 
a patient with microalbuminuria were also fractionated by SEC and assayed for T-AN, H-AN, albumin and 
creatinine (Fig. 4) and the background data for these 3 cases are shown in Table 1. Both T-AN and H-AN levels 
were higher in the urine of patients with either microalbuminuria or macroalbuminuria, which could be mainly 
attributed to the appearance of HMW and MMW in the urine of those patients.
Figure 2.  Analytical performance of T-AN and H-AN assays. Dose and response curves for T-AN (a) and 
H-AN (b) assays. Dilution linearity of T-AN (c) and H-AN (d) assays.
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Figure 3.  Correlation between two assays for T-AN levels in the urine; a manual assay (Manual ICT-EIA) and 
a fully automated T-AN assay on HI-1000 (T-AN.) (a) All samples, (b)samples with a measurement of T-AN 
levels by the manual ICT-EIA < 50 μg/gCr.
Figure 4.  Composition of adiponectin in urine from patients with normoalbuminuria (a) and 
microalbuminuria (b). Urine samples from a patient with normoalbuminuria and a patient with 
microalbuminuria were separated by SEC and fractions were measured with T-AN and H-AN assays.
Table 1.  Urinary biomarker concentrations in diabetic patients with normoalbuminuria, microalbuminuria, 
and macroalbuminuria shown in Figs. 1 and 4.
Albuminuria
Normo (Fig. 4a) Micro (Fig. 4b) Macro (Fig. 1)
Albumin (mg/gCr) 7.5 83 2926
T-AN (μg/gCr) 5.7 19 78
H-AN (μg/gCr) 0.14 8.6 78
eGFR (mL/min/1.73m2) 100 34 43
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Relationship of T-AN and H-AN levels with DKD severity. Urine samples from 77 patients with 
either type 1 or type 2 diabetes and 97 non-diabetic controls were tested for T-AN, H-AN, albumin and cre-
atinine. Characteristics of these two groups are summarized in Table 2. In this study, the non-diabetic subject 
group was a younger population (42, 34–49; Median, 25th-75th percentiles) than the diabetic patient group (62, 
52–69), which might affect the levels of urinary biomarkers. Thus, a subgroup of 42–64 years old only was also 
investigated. The age of inclusion criteria in the analysis of 42–64 years was determined by the maximum age 
of non-diabetic subjects and the minimum age at which no statistical difference of age between the groups was 
observed.
Spearman’s rank correlation coefficients between conventional biomarkers and T-AN or H-AN, all of which 
were normalized by creatinine, using all subjects’ data are summarized in Table 3. T-AN and H-AN levels were 
strongly correlated with the albumin level in subjects with/without diabetes. In addition, the correlation between 
the T-AN level and eGFR and between the H-AN level and eGFR were stronger than that of the albumin level 
and eGFR especially in patients with diabetes. The same trends were observed in the age-restricted subgroup of 
42–64 years old only (Table S2).
Levels of urinary biomarkers and eGFR at each albumin stage for all subjects are shown in Fig. 5a. Both 
T-AN and H-AN levels increased and eGFR decreased as the albumin stage progressed. Compared to non-
diabetic subjects, T-AN and H-AN levels were increased significantly in diabetic patients of stage A1, A2, and 
A3. Similarly, T-AN and H-AN were elevated in stage A2 and A3 compared to stage A1. And further, T-AN and 
H-AN were elevated in A3 compared to A2. The level of eGFR was also significantly decreased in stages A1, A2, 
and A3 compared with non-diabetic controls and a significant decrease was confirmed at stage A3, but not A2, 
compared to A1.
In the analysis of the age-restricted subgroup of 42–64 years old only (Fig. 5b), similar increases in T-AN and 
H-AN levels were observed over non-diabetic subjects, increasing from A1 to A2 to A3 stages. Elevations were 
significant in all albumin stages over non-diabetic subjects. Further, H-AN levels were significantly elevated in 
stages A2, A3 over A1. But for T-AN, only stage A3 was significantly elevated over stage A1. For eGFR, only stage 
A3 showed a significant decrease from non-diabetic subjects or albumin stage A1 subjects.
Similar data analysis was performed based on eGFR stage in all subjects (Fig. 6a). Both T-AN and H-AN levels 
increased significantly as the eGFR stage progressed compared to non-diabetic subjects, with the exception of 
the H-AN levels of the G1 group which were not elevated. Albumin levels were increased significantly at eGFR 
stages G2, G3b, and G4 over non-diabetic subjects. Using G1 stage as baseline, no significant increase in T-AN 
was observed in progressive eGFR stages since the level of T-AN was already significantly high at the G1 stage. 
For H-AN, stage G3b levels were significantly elevated over G1 levels and this was observed also for albumin.
In the analysis of the age-restricted subgroup of 42–64 years old only (Fig. 6b), albumin and H-AN levels 
were statistically significantly increased, compared with non-diabetic subjects, at stage G3b whereas T-AN was 
statistically significantly increased in stages G2 and G3b. Similar to the results from all participants, T-AN and 
Table 2.  Characteristics of non-diabetic and diabetic groups. For comparison of differences between two 
groups, the Mann–Whitney’s U test was used.
All subjects Non-diabetic subjects (n = 97) Patients with diabetes (n = 77) p
Gender (Male/female) 64/33 38/39
Age (years) 42 (34, 49) 62 (52, 69) < 0.001
BMI (kg/m2) 24 (21, 26) 24 (22, 28) 0.098
Type of diabetes (1/2) N/A 31/46
Duration of diabetes (years) N/A 12 (7.5, 18)
HbA1c (%) 5.4 (5.2, 5.6) 7.1 (6.7, 7.7) < 0.001
eGFR (mL/min/1.73 m2) 88 (76, 96) 68 (55, 83) < 0.001
Urinary albumin (mg/gCr) 2.3 (1.5, 3.5) 4.2 (2.1, 35) < 0.001
T-AN (μg/gCr) 0.89 (0.63, 1.2) 3.8 (1.4, 9.6) < 0.001
H-AN (μg/gCr) 0.040 (0.020, 0.063) 0.21 (0.060, 1.5) < 0.001
42–64 years old only Non-diabetic subjects (n = 49) Patients with diabetes (n = 41) p
Gender (Male/Female) 32/17 20/21
Age (years) 49 (44, 56) 54 (46, 59) 0.083
BMI (kg/m2) 24 (21, 27) 25 (22, 29) 0.38
Type of diabetes (1/2) N/A 20/21
Duration of diabetes (years) N/A 9 (5.0, 16)
HbA1c (%) 5.5 (5.2, 5.8) 7.2 (6.8, 8.1) < 0.001
eGFR (mL/min/1.73 m2) 79 (69, 90) 77 (60, 88) 0.11
Urinary albumin (mg/gCr) 2.4 (1.7, 3.9) 3.3 (1.9, 36) 0.011
T-AN (μg/gCr) 1.1 (0.66, 1.8) 2.5 (1.2, 6.5) < 0.001
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H-AN levels in the stage G3a and T-AN, H-AN and albumin levels in the stage G4 were high, but the small 
number of patients prevents statistical significance to be achieved.
Whereas T-AN and H-AN levels were strongly associated with albumin stage, higher T-AN levels were 
observed at earlier stages of eGFR than was albumin. These results indicate that T-AN and H-AN may be useful as 
early biomarkers for DKD, although the response of T-AN and H-AN levels to DKD severity is slightly different.
Discussion
We developed assays for measuring the amount of two adiponectin isoforms; one for T-AN levels and another 
for H-AN levels. To measure T-AN levels, two different monoclonal antibodies, both of which recognize the 
globular domain of adiponectin, were used to detect all types of adiponectin. In another assay, clone 38 antibody, 
which detects only HMW and MMW adiponectin (Fig.S1), was used as both capture and detection to react only 
with HMW, and weakly with MMW adiponectin. One of the strengths of our T-AN and H-AN assays is that 
they are fully automated on an immunoassay system, HI-1000. As a result, the measurement time was shortened 
from three days for the conventional manual ICT-EIA to approximately one hour. Our fully automated T-AN 
and H-AN assays also show high reproducibility, good dilution linearity, and ultra-high sensitivity. In fact, the 
LoDs were 0.05 and 0.11 pg/mL for T-AN and H-AN assays, respectively, which would enable accurate measure-
ment of very low levels of adiponectin in the urine of non-diabetic subjects (Fig. 5). Previous studies on urinary 
adiponectin used multiple commercially available Enzyme-linked immunosorbent assay  kits4,7,8,10. These assays 
may differ in their reactivity to multiple isoforms of adiponectin, and reactivities of these assays to urinary adi-
ponectin isoforms are still unknown. In this study, we developed two highly reproducible and sensitive assays 
that are fully automated, and have been characterized in detail with respect to the reactivity of these assays to all 
urinary adiponectin isoforms using SEC fractions of urine samples (Figs. 1 and 4).
Previous studies conducted by western blotting analysis have identified monomers, LMW and MMW adi-
ponectin in  urine6,13. Our ultrasensitive manual ICT-EIA could identify four types of adiponectin (HMW, MMW, 
LMW and monomer) by measurement of urine samples after  SEC29. As described above, the fully automated 
and newly developed T-AN and H-AN assays are also highly sensitive enough to measure extremely low con-
centrations of each adiponectin isoform in urine samples after SEC (Figs. 1 and 4). Thus, it was possible to 
compare the level of each adiponectin isoform in urine between three patients with diabetes, who have differ-
ent stages of albuminuria, by using SEC samples of urine from them. Consistent with previous  reports29, four 
types of adiponectin (HMW, MMW, LMW and monomer) were detected. Moreover, the results suggested that 
most urinary adiponectin in patients with normoalbuminuria are monomer and LMW isoform, whereas the 
proportion of macromolecules, such as HMW and MMW adiponectin, are higher in patients with albuminuria 
(Table 1 and Fig. 4). Several mechanisms of adiponectin excretion into the urine have been proposed in the 
 past8–10,12,13. Detection of more macromolecular adiponectin in patients with albuminuria supports a possibil-
ity that disruption of the glomerular molecular barrier may substantially contribute to an increased urinary 
adiponectin excretion in DKD.
Furthermore, we also showed that T-AN and H-AN levels were moderately to highly correlated with UAER 
and eGFR, which indicates that they may be used as biomarkers to tell the progression of DKD (Table 3). In fact, 
when T-AN and H-AN levels were measured in non-diabetic subjects and diabetic patients with various levels 
of DKD, T-AN level in diabetics became significantly higher than that in non-diabetic subjects from as early 
as the G1 stage (Fig. 6). A similar trend was observed with the age-restricted subgroup. H-AN levels showed a 
Table 3.  Correlation between conventional biomarkers and T-AN or H-AN in the urine. ND, Non-diabetic 
subjects; DM, Type 1 and type 2 diabetes patients. Spearman’s correlation coefficients were calculated.
ND DM ND + DM
Albumin
T-AN
 r 0.25 0.70 0.54
 p 0.014 < 0.001 < 0.001
H-AN
 r 0.47 0.75 0.66
 p < 0.001 < 0.001 < 0.001
eGFR
Albumin
 r 0.013 − 0.32 − 0.23
 p 0.90 0.0048 0.0025
T-AN
 r − 0.079 − 0.39 − 0.43
 p 0.44 < 0.001 < 0.001
H-AN
 r 0.0017 − 0.49 − 0.38
 p 0.99 < 0.001 < 0.001
7
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:15869  | https://doi.org/10.1038/s41598-020-72494-6
www.nature.com/scientificreports/
similar trend to albumin, with elevations observed in diabetics with > G2 stage when compared with those in 
non-diabetics. Thus, T-AN and H-AN levels may serve as biomarkers for DKD: usage of T-AN assay to detect a 
wide variety of adiponectin isoforms may enable detection of early pathological changes in the kidney. On the 
other hand, H-AN levels could be a biomarker of more progressed DKD.
In conclusion, we developed two ICT-EIAs for measuring T-AN and H-AN which showed high reproduc-
ibility, good dilution linearity, and ultra-high sensitivity. The conventional ICT-EIA method took 3 days to 
test samples, but the newly developed assays are fully automated and can finish an assay in 1 h by using a 
Figure 5.  Levels of urinary biomarkers and eGFR at each albumin stage for all subjects (a) and subjects aged 
42–64 years old only (b). Albumin stages were classified according to the following definition. A1: < 30, A2: 
30–299, A3: ≧ 300 mg/gCr. Kruskal–Wallis test and Steel–Dwass test were used for comparisons. ND: Non-
diabetic subjects, DM: patients with Type 1 or type 2 diabetes, *P < 0.05 and **P < 0.01 compared with ND, 
†P < 0.05 and ††P < 0.01 compared with A1.
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high-sensitivity immunoassay system, the HI-1000. Furthermore, using these new assays, we showed that both 
T-AN and H-AN levels in the urine may be increased in patients with diabetes and they may have clinical sig-
nificance in tackling DKD.
The limitations of this study are limited clinical data, cross-sectional studies, age-biased controls, and lack 
of accurate diagnosis of diabetic renal disease, which could be made by a biopsy. In the future, the usefulness 
of urinary adiponectin levels as a biomarker of DKD should be tested in larger prospective studies, which is 
currently underway.
Figure 6.  Levels of urinary biomarkers at each eGFR stage for all subjects (a) and subjects aged 42–64 years 
old only (b). eGFR stages were classified according to the following definition. G1: ≧ 90, G2: 60–89, G3a: 45–59, 
G3b: 30–44, G4: 15–29 ml/min/1.73m2. Kruskal–Wallis test and Steel–Dwass test were used for comparisons. 
ND: Non-diabetic subjects, DM: patients with Type 1 or type 2 diabetes, *P < 0.05 and **P < 0.01 compared with 
ND, †P < 0.05 and ††P < 0.01 compared with G1.
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Methods
Urinary adiponectin assay. Buffers. 10 mM sodium phosphate buffer (pH 7.0) containing 0.1 M sodium 
chloride (NaCl), 1.0  mM magnesium chloride  (MgCl2), 0.1% sodium azide  (NaN3) and 0.1% bovine serum 
albumin (BSA) was used for dialysis and dilution of urine samples. 0.1  M 2-(N-morpholino)ethanesulfonic 
acid (MES) buffer (pH 6.5) containing 0.15 M NaCl, 1.0 mM  MgCl2, 0.1 mM zinc chloride  (ZnCl2), 0.1%  NaN3 
and 0.1% BSA was used for dilution of detection antibody conjugates. The same composition without  MgCl2 
and  ZnCl2 was used for dilution buffer for capture antibody conjugates. 0.1 M MES buffer (pH 6.5) containing 
2.5 mM Nε-DNP-L-lysine hydrochloride (DNP), 2% casein sodium and 0.1%  NaN3 was used for elusion buffer 
in ICT-EIA. HISCL washing solution (Sysmex, Hyogo, Japan) was used for washing buffer.
Antibodies and antigens. Different types of antibodies were employed to measure T-AN levels and H-AN levels, 
respectively. Monoclonal mouse anti-human Adiponectin/Acrp30 antibody (Product code: MAB10651, Clone: 
166126, Antibody Registry: AB_2221612) and monoclonal mouse anti-human Adiponectin/Acrp30 antibody 
(Product code: MAB1065, Clone: 166128, Antibody Registry: AB_2273512) were chosen as capture and detec-
tion antibodies, respectively, for T-AN assay. Monoclonal mouse anti-human Adiponectin/Acrp30 antibody 
(Clone: 38, Sysmex, Hyogo, Japan) was used for both capture and detection antibodies for H-AN assay. Recom-
binant Human Adiponectin (Oriental yeast, Tokyo, Japan) was used as calibrators.
Preparation of capture and detection antibody conjugates. For T-AN assays, thiol groups were introduced into 
the capture antibody (Clone: 166126) using PIERCE SATA (N-succinimidyl S-acetylthioacetate) (Thermo 
Fisher Scientific Inc., Waltham, MA) and the antibody was then conjugated with 6-maleimidohexanoyl-DNP 
and 6-maleimidohexanoyl-biocytin30,31. Other monoclonal antibodies were digested with pepsin (Roche, Basel, 
Switz) to F(ab’)2, which was further reduced to obtain Fab’. Fab’ fragments were conjugated with 6-maleimi-
dohexanoyl-DNP-biotinyl-BSA as capture antibody conjugate and with alkaline phosphatase from calf intestine 
(Oriental yeast, Tokyo, Japan) using N-(ε-maleimidocaproyloxy)succinimide (Dojindo, Kumamoto, Japan) as 
detection antibody  conjugate30,31.
Preparation of protein‑coated magnetic particles. Carboxyl groups on their surface of magnetic particles 
(JSR, Tokyo, Japan) were activated by using 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, hydrochloride 
(Dojindo, Kumamoto, Japan) and N-Hydroxysuccinimide (Tokyo Chemistry Industry, Tokyo, Japan). The acti-
vated magnetic particles were mixed and coated with monoclonal mouse anti-DNP antibody (Clone: 1853, Sys-
mex, Hyogo, Japan) and Biotinyl-BSA, respectively.. Biotinyl-BSA-coated magnetic particles were then reacted 
with streptavidin (MilliporeSigma, St.Louis, MO)30,31.
Immune complex transfer enzyme immunoassay (ICT‑EIA) for adiponectin. The protocol of the ICT-EIA for 
T-AN was as follows (Fig. 7): 70 μL of sample was mixed with 40 μL of detection antibody conjugate and incu-
bated for 3.4 min. 40 μL of capture antibody conjugate was added and incubated for 23.8 min. After adding 
20 μL of anti-DNP antibody coated magnetic particles, immune complexes were captured onto the surface of 
the beads during 11.3 min of incubation. After washing, the immune complexes were released from the beads 
surface during 4.6 min of incubation in 110 μL of elution buffer. With magnetic particles magnetized, 80 μL of 
the supernatant of the reaction solution containing the immune complexes was taken and transferred to another 
vial. After adding 30 μL of streptavidin coated magnetic particles, immune complexes were re-captured onto 
the surface of the beads during 5.3 min of incubation. All reactions up to this point were performed at 37 °C. 
The bead was then washed, and the bound alkaline phosphatase activity was assayed by chemiluminescence 
with HISCL substrate reagent set (Sysmex, Hyogo, Japan) for 5.0 min at 42 °C. H-AN was measured in a similar 
manner, except that the reaction time with the detection antibody conjugate was 5.8 min and with the capture 
Figure 7.  Assay scheme of ICT-EIA. All reactions were performed on HI-1000. Immune complexes formed in 
the liquid phase are captured by anti-DNP antibody beads. After washing, the immune complex is released into 
the liquid phase by the addition of large amounts of DNP-Lys and re-captured by streptavidin beads. After a 
second wash, the amount of chemiluminescence produced by the enzyme–substrate reaction is  measured24.
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antibody conjugate was 9.4 min. All reactions were performed automatically using a high-sensitivity immunoas-
say system, the HI-1000 (Sysmex, Hyogo, Japan).
Assay characterization. Calibration curves were generated with 9 calibrators spanning a dynamic range of 0 to 
1000 pg/mL for T-AN assay and 6 calibrators spanning a dynamic range of 0 to 10,000 pg/mL for H-AN assay. 
The LoD was calculated as the concentration which is equivalent to the mean plus 3 standard deviations of low 
concentration samples. The calibrators were measured 10 times to determine reproducibility, and coefficients of 
variations were calculated. In a dilution linearity evaluation, a dialyzed urine sample was diluted with dilution 
buffer to achieve 4 new concentrations. These 4 dilutions and the original calibrator were measured 3 times, 
respectively, and the difference between the concentration of the original sample and the expected concentra-
tions calculated from the concentration of the diluted samples and their dilution factors were compared.
clinical study
Subjects and samples. Nighty seven non-diabetic subjects from an occupational-based cohort study held 
in Tokushima prefecture and 77 outpatients with type 1 or type 2 diabetes in Tokushima University Hospital 
were enrolled in this study. Non-diabetic subjects were defined as satisfying the following three points: fast-
ing blood glucose level was less than 126 mg/dl, HbA1c was less than 6.5%, and no diabetes medication was 
prescribed. Diabetes was defined by physicians according to the diagnostic criteria of Japan Diabetes  Society32. 
Blood samples were drawn from an antecubital vein of subjects. Early morning urine samples were collected 
after overnight fasting. The urine samples (10 mL) were mixed with 0.1 mL of 10% BSA and  NaN3 and dialyzed 
against dialysis buffer at 4 °C overnight. Dialyzed urine samples were kept frozen at -30 °C until analysis.
Size exclusion chromatography (SEC) of urine. Three randomly chosen urine samples (1.0 mL) from 
patients with normoalbuminuria, microalbuminuria and macroalbuminuria, respectively, were selected from 
patients with diabetes and separated by SEC using an AKTA explorer 10S (GE Healthcare, Tokyo, Japan) on a 
column of HiLoad 16/60 Superdex 200 prep grade (1.6 × 60 cm) (GE Healthcare). An aliquot of each fraction 
was used for T-AN and H-AN assays.
Measurements of biomarkers in urine. Dialyzed urine samples were analyzed for adiponectin, using 
T-AN and H-AN as described above. They were also analyzed for albumin, by an ICT-EIA for  albumin29 and 
creatinine by a commercially available creatinine kit (Creatinine-test Wako, FUJIFILM Wako Pure Chemical 
Corporation, Osaka, Japan). Urinary adiponectin and albumin concentrations were normalized by the urinary 
creatinine (Cr) concentration. Urine samples after SEC fractionation were also tested for T-AN and H-AN.
Statistical analysis. The Shapiro–Wilk test was used to examine whether the measurements of biomark-
ers were normally distributed. For biomarker correlation analysis, Spearman’s correlation coefficients were 
calculated. For comparison of differences between two or multiple groups, the Mann–Whitney’s U test or the 
Kruskal–Wallis test and Steel–Dwass test were used, with 5% as the criterion for significance.
ethical considerations. The study protocol was approved by the ethical committee of Tokushima Bunri 
University (No. H29-17) and by the ethical committee of Tokushima University Hospital (No. 2894–1 for dia-
betics and No. 3087 for non-diabetics); all diabetic participants gave written informed consent. Non-diabetic 
participants were participants of an occupational-based cohort study, which was also approved by the ethical 
committee of Tokushima University Hospital (No. 662), and gave written informed consent to this cohort study. 
In No. 3087, non-diabetic participants were provided an easy mode to opt-out by a hand-out and online so that 
participants are well-informed about this study and their opportunity to indicate refusal. All methods were per-
formed in accordance with the relevant guidelines and regulations.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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